Home About Products ProDermaCel™ DermX OralX Research Markets Contact News	ProCertus has identified three products for initial clinical testing. DermX and ProDermaCel™ share a common active agent and are both applied to squamous skin using the same delivery vehicle. They will be tested for safety and efficacy in concurrent Phase I/II clinical studies in cancer patients. OralX has been formulated for topical application to oral mucosa and will be tested in separate safety and efficacy studies. ProDermaCel™, a topically applied pharmaceutical, will protect normal hair follicle stem cells to prevent the loss of hair (alopecia) suffered by... DermX, a topically applied pharmaceutical, will protect normal skin stem cells from radiotherapy and thus prevent the dermatitis (skin burn)... OralX, a topically applied pharmaceutical, will protect normal oral, pharyngeal and esophageal mucosa from the mucositis that commonly...